Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers
- 1 October 2015
- journal article
- research article
- Published by Elsevier in Joint Bone Spine
- Vol. 82 (5) , 330-337
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registryArthritis & Rheumatism, 2009
- Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritisArthritis & Rheumatism, 2007
- The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practiceAnnals of the Rheumatic Diseases, 2007
- Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?Annals of the Rheumatic Diseases, 2007
- Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practiceRheumatology, 2007
- Therapy of patients with rheumatoid arthritis: Outcome of infliximab failures switched to etanerceptArthritis Care & Research, 2007
- Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effectsAnnals of the Rheumatic Diseases, 2007
- Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled studyAnnals of the Rheumatic Diseases, 2006
- Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year periodArthritis Research & Therapy, 2006
- Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make senseAnnals of the Rheumatic Diseases, 2003